Identification and Validation of Three PDAC Subtypes and Individualized GSVA Immune Pathway-Related Prognostic Risk Score Formula in Pancreatic Ductal Adenocarcinoma Patients

Deyu Zhang,1 Meiqi Wang,2 Lisi Peng,1 Xiaoli Yang,1 Keliang Li,2 Hua Yin,1 Chuanchao Xia,1 Fang Cui,1 Haojie Huang,1 and Zhendong Jin1

1Department of Gastroenterology, Shanghai Hospital, Shanghai, China
2Department of Gastroenterology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

Correspondence should be addressed to Zhendong Jin; zhendongjin@163.com

Received 3 November 2021; Revised 24 November 2021; Accepted 30 November 2021; Published 27 December 2021

Background. With the progress of precision medicine treatment in pancreatic ductal adenocarcinoma (PDAC), individualized cancer-related medical examination and prediction are of great importance in this high malignant tumor and tumor-immune microenvironment with changed pathways highly enrolled in the carcinogenesis of PDAC. Methods. High-throughput data of pancreatic ductal adenocarcinoma were downloaded from Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) database. After batch normalization, the enrichment pathway and relevant scores were identified by the enrichment of immune-related pathway signature using gene set variation analysis (GSVA). Then, cancerous subtype in TCGA and GEO samples was defined through the NMF methods by cancertypes packages in R software, respectively. Subsequently, the significance between the characteristics of each TCGA sample and cancer type and the significant prognosis-related pathway with risk score formula is calculated through t-test and univariate Cox analysis. Next, the prognostic value of gained risk score formula and each significant prognosis-related pathway were validated in TCGA and GEO samples by survival analysis. The pivotal hub genes in the enriched significant prognosis-related pathway are identified and validated, and the TIMER database was used to identify the potential role of hub genes in the PDAC immune environment. The potential role of hub genes is promoting the transdifferentiation of cancer-associated fibroblasts. Results. The enrichment pathway and relevant scores were identified by GSVA, and 3 subtypes of pancreatic ductal adenocarcinoma were defined in TCGA and GEO samples. The clinical stage, tumor node metastasis classification, and tumor grade are strongly relative to the subtype above in TCGA samples. A risk formula about GSVA significant pathway “GSE45365_WT_VS_IFNAR_KO_CD11B_DC_MCMV_INFECTION_DN × 0.80 + HALLMARK_GLYCOLYSIS × 16.8 + GSE19888_CTRL_VS_T_CELL_MEMBRANES_ACT_MAST_CELL_DN × 14.4” was identified and validated in TCGA and GEO samples through survival analysis with significance. DCN, VCAN, B4GALT7, SDC1, SDC2, B3GALT6, B3GAT3, SDC3, GPC1, and XYLT2 were identified as hub genes in these GSVA significant pathways and validated in silico. Conclusions. Three pancreatic ductal adenocarcinoma subtypes are identified, and an individualized GSVA immune pathway score-related prognostic risk score formula with 10 hub genes is identified and validated. The predicted function of the 10 upregulated hub genes in tumor-immune microenvironment was promoting the infiltration of cancer-associated fibroblasts. These findings will contribute to the precision medicine of pancreatic ductal adenocarcinoma treatment and tumor immune-related basic research.

1. Introduction

Pancreatic ductal adenocarcinoma (PDAC) is a life-threatening disease with the lowest survival rates among major cancers, and its mortality rate per year is increasing from 9th to 7th [1]. Positive results of computed tomography (CT) often only occur on terminal patients with PDAC, with a delayed diagnosis and poor prognosis of patients [2]. Additionally, the poor prognosis of patients with PDAC is also due to the high recurrence rate and early distant...
metastasis [3]. Aiming to prompt diagnosis and treatment, some advanced effective procedures have been put forward, including nucleic acid in circulating cancer cells, long noncoding RNA in an extracellular vesicle, and some pivotal clinical characteristics [4–6]. Besides these, some other individualized diagnostic methods based on sequencing and key pathway need to be identified.

Several original gene-related diagnostic and prognostic signatures have been developed to estimate a clinical outcome and instruct precise treatment of various types of patients with cancer, including pulmonary carcinoma [7] and gastric cancer [8]. Meanwhile, some miRNA-based diagnostic and prognostic signatures also show great utilization potentialities in prognosis prediction and treatment, such as the preferable predictive value of screened miRNA in lymph-gland tumor [9] and a lncRNA-based formula developed for renal cancer [10]. As described above, most of the current research studies focus on the predicting potential of a cluster of screened genes, namely, lncRNAs and miRNAs. The research studies on carcinogenesis-related pathways need to be clarified, and screening a cluster of prognostic-related pathways can facilitate in cancer treatment.

The gene set variation analysis (GSVA) is a nonparametric, unsupervised algorithm. The GSVA does not require preregrouping of samples and can calculate enrichment scores for specific sets of genes in each sample. Additionally, GSVA transforms gene expression data from an expression matrix of individual genes as traits to an expression matrix of specific gene sets as traits. The results of gene enrichment were quantified by GSVA, which can be more convenient for follow-up statistical analysis [11]. The GSVA method has been well performed on some research studies that focus on pathology mechanism, such as GSVA was used on calculating T-cell receptors and ligands related to T-cell failure and indicating T-cell apoptosis and activated expression of cell cycle genes in the process of neuroblastoma [12].

In this study, we used the NMF method to identify PDAC subtypes and developed and verified a GSVA-based immune pathway formula aiming to predict the prognostic clinical outcomes of patients and identify the pivotal pathway. Then, the hub genes in these pivotal pathways are identified and the potential roles in the tumor-immune microenvironment were predicted. Our findings could facilitate the precise treatment and basic research of PDAC.

2. Materials and Methods

2.1. Data Source. The gene expression matrixes with paired clinical data are downloaded in The Cancer Genome Atlas (TCGA) database (https://cancergeno.me.nih.gov/) named TCGA-PDAC (TCGA PDAC: 4 paracarcinoma tissue and 178 cancers with survival data) and two datasets in Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo/), GSE28735, and GSE62452. (GSE28735: 45 paracarcinoma tissue and 45 carcinoma tissue with survival data. GSE62452: 61 paracarcinoma tissue and 69 carcinoma tissue with survival data.)

2.2. Batch Normalization. The batch effect is part of the measurement results because of the different experimental conditions. The purpose of correcting the batch effect is to reduce the irrelevant differences between batches and to identify the differences between different biological states. To remove the impact of batch effect between GSE28735 and GSE62452, the SVA package was used in R software [13].

2.3. Gene Set Variation Analysis. Gene set variation analysis (GSVA) is a nonparametric unsupervised analysis method mainly used to evaluate the gene set enrichment results of sequencing. The expression matrix of genes is transformed into the expression matrix of pathways in different samples to evaluate different metabolic pathways enriched in different samples. It mainly is to explain the causes of phenotypic differences from a bioinformatic perspective. In this study, we perform GSVA using GSVA package in R software, and an immune-related gene set c7.immune-sigdb_HALLMARK was used in GSVA.

2.4. Cancer Subtype Identification. CancerSubtypes package [14] in R software was exerted on TCGA pathway expression matrix with survival data and validated on combined GEO data (GSE28735 and GSE62452). Non-negative matrix factorization (NMF) is a powerful method for reducing the dimension of data and has a wide range of applications in the identification of functional part for complex data with several dimensions. We used the “NMF” and “factoextra” packages to perform NMF on TCGA and GEO datasets above to further confirm the differentiation among the acquired PDAC subtypes.

2.5. Survival Analysis. Survival analysis is the method to analyze and infer the survival time of patients with PDAC in different groups based on clinical data from TCGA and GEO, aiming to study the relationship among survival time, patients’ outcomes, and various influencing factors. In our study, survival analysis was performed using the survival package in R software.

2.6. Visualization and Data Statistics. All visualization and data statistics were exerted in R software. In particular, complexHeatmap package was used on TCGA-PDAC data to identify the classification of subtypes. Differential analysis of gene sets was calculated using the limma package. Then, LASSO regression was exerted using the Glimnet package. The ClusterProfiler package in R software was used to identify key KEGG pathway in the pivotal immune-related pathway, and Cytohubba package in Cytoscape software was used to screen hub genes in pivotal immune-related pathway above.

2.7. Database Manipulation. TIMER database (Tumor Immune Estimation Resource:https://cistrome.shinyapps.io/timer/) includes “EPIC,” “Mcpcounter,” “Xcell,” and “Tide.” TIMER was used to estimate the tumor immune infiltration by combining the algorithm above and TCGA
sequencing data. The GEPIA (Gene Expression Profiling Interactive Analysis) is another database containing TCGA tumor sequencing data and GTEx normal tissue sequencing data, and it was used to identify the expression of hub genes among pancreatic tumor tissue and common tissue.

3. Results

3.1. Transitional Signatures of Immune-Related Pathway among PDAC and Paracarcinoma Tissue. Figure 1 illustrates the procedure of our study. First, to identified the transitional signatures of immune-related pathway among PDAC and paracarcinoma tissues, PDAC sequencing data were screened and downloaded in TCGA (TCGA PDAC: 4 paracarcinoma tissues and 178 cancerous tissues with survival data) and GEO databases (GSE28735: 45 paracancers and 45 cancers with survival data, GSE62452: 61 paracancers and 69 cancers with survival data). Then, the hallmarks get set, and immune-related pathways ("c7.immune-related pathways") contained 4922 gene sets were downloaded from GSAVA (https://www.gseamsigdb.org/ gsea/msigdb/index.jsp).

GSVA was used on the TCGA-PDAC cohort, and the enrichment score is clustered and visualized (Figure 2(a)). After batch normalization of GSE28735 and GSE62452, GSVA was exerted in this GEO cohort (Figure 2(b)). The screened gene sets appear to classify cancers and paired paracarcinoma tissues into several subtypes.

3.2. Identification of PDAC Subtypes and the Relevance between PDAC Subtype and Clinical Characteristics. After the expression of immune-related pathway and gene sets in two PDAC cohorts had been manipulated (4,922 gene sets), cancer subtypes are identified by the "CancerSubtypes" package in R software. By using the NMF method, , 3 had been identified as the best cutoff number of cluster, which means PDAC could be separated into 3 subtypes by the GSVA immune-related pathway score of each sample (Figure 3(a)). Then, Figure 3(b) shows the three divided clusters. Combining with clinical data, the different prognosis among the three PDAC subtypes was identified (Figure 3(c)). In particular, cluster 1 shows a significant favorable prognosis. Cluster 2 displays a medium prognosis among the 3 clusters, and cluster 3 reveals the poorest prognosis. Cluster display plot and silhouette width plot show high credibility subtype identification (0.93 average silhouette width, Figures 3(e) and 3(d)). Subsequently, these 3 subtype separation methods were validated on GEO cohorts (Supplementary Materials (available here)).

Then, the relevance between clinical characteristic and each divided subtype is confirmed in the TCGA-PDAC cohort. In brief, patients in subtype 1 are often accompanied by high clinical stage, pathologic grade (G), and bad TN classification. Patients in subtype 2 are often together with moderate clinical stage, pathologic grade (G), and TN classification, and patients in subtype 3 often have good to moderate clinical stage, pathologic grade (G), and TN classification with statistical significance. The differently expressed pathways with significance by pairwise comparison were enriched and calculated in each cluster (adjusted P value <0.05). A total of 93 significant pathways were enriched as common differently expressed pathways in the 3 subtypes (Figure 4(b)). The details of the clinical relevance among subtypes are shown in Table 1. The patient status, R0 resection rate, tumor size, TMN classification, the WHO classification, pathological grade, and alcohol history among these 3 subtypes show great differentiation (P < 0.05). Patients in subtype 1 are inclined to have the worst condition in these clinical characteristic, while patients in subtype 2 group tend to get the best condition.

3.3. Calculation and Validation of Prognostic Signaling Pathway and Gene Set-Based Formula. Combining with the survival data of patients, univariable Cox regression analysis was used to screen on 93 intersected gene sets and pathways. Four gene sets and 1 pathway were screened, including GSE45365_WT_VS_IFNAR_KO_CD11B_DC_MCMV_INFECTION_DN, GSE20715_0H_VS_48H_OZONE_LUNG_DN, GSE13411_PLASMA_CELL_VS_MEMBRANE_BCELL_UP, GSE19888_CTRL_VS_T_CELL_MEMBRANES_ACT_MAST_CELL_DN and GLYCOLYSIS pathway (Table 2). To identify the pivotal part of these gene sets, LAASO regression is exerted in Figures 5(a) and 5(b), and 2 gene sets and 1 pathway were identified with risk coefficient (Figure 5(c)). Their prognostic value was then validated by survival analysis based on PDAC-TCGA (Figures 5(d)–5(f)) and GSE82735 and GSE62452 (Figures 5(g)–5(i)). The formula was constructed based on the screened gene sets and risk coefficient: Risk score = GSE45365_WT_VS_IFNAR_KO_CD11B_DC_MCMV_INFECTION_DN * 0.80 + HALLMARK_GLYCOLYSIS * 16.8 + GSE19888_CTRL_VS_T_CELL_MEMBRANES_ACT_MAST_CELL_DN + 14.4. The risk score based on the formula was calculated. Then, survival analysis was executed on the TCGA-PDAC cohort and validated GSE28735 and GSE62452 cohorts (Figures 5(j) and 5(k)).

3.4. Identification of Significant Pathway and Hub Genes in the Screened Prognosis-Related Gene Sets. Genes in the 3 prognosis-related gene sets and pathways were extracted, and gene ontology enrichment analysis was performed. Several cancer-related metabolism GO term and "tight junction" are identified in Figure 6(a). Then, KEGG enrichment analysis is exerted as Figure 6(b). Some pivotal pathways are involved, including the "HIF-1 signaling pathway" and "pyruvate metabolism" (Figure 6(b)). Additionally, we performed protein-protein interaction analysis, and the top 10 ranked hub genes are identified by enriched scores, including DCN, VCAN, B4GALT7, SDC1, SDC2, B3GALT6, B3GAT3, SDC3, GPC1, and XYL'T2.

3.5. Validation of the Hub Genes and Estimating Their Potential Roles in Promoting the Infiltration of Cancer-Associated Fibroblasts (CAFs) in Tumor Environments. Then, the potential roles of the screened 10 hub genes in tumor-
Figure 1: Flow chart of our study.

Figure 2: Heatmap of TCGA and GEO data. (a) Enrichment score of immunologic and hallmark genes between cancers and paracarcinoma tissues in TCGA-PDAC. (b) Enrichment score of immunologic and hallmark gene cancers and paracarcinoma tissues in GSE28735 and GSE62452.
Figure 3: Continued.
immune microenvironment were predicted on the TIMER database. Among all the tumor-related immune cells, the 10 hub genes were significantly enriched in cancer-associated fibroblasts (CAFs) (Figure 7). Finally, upregulation of the 10 hub genes was validated in the GEPIA database. All 10 hub genes are upregulated in cancer tissue compared to normal pancreas. Eight hub genes, including DCN, VCAN, SDC1, B3GALT6, B3GAT3, SDC3, GPC1, and XYLT3, are significantly upregulated in PDAC tissue.

4. Discussion

As a fatal malignant tumor, PDAC causes a huge social health burden and patients could neither be directly diagnosed in the early stage nor be accurately predicted the clinical outcome. At this point, the prognostic marker is in great need for the treatment of patients with PDAC [15].

In this study, we used bioinformatic and statistical methods to screen the biomarkers with great prognostic sensitivity. Through the combination of the GSVA method, NMF algorithm, and the obtained sequencing data from the TCGA database, we put forward a new grouping method to predict the prognosis of patients with PDAC and validate in GEO samples. In fact, several studies have manipulated on analyzing the subtype of PDAC using the machine-learning algorithm. Wu et al. reported a procedure to cluster PDAC samples into 2 subtypes based on TCGA sequencing data. However, the K-means algorithm was used in the study of Sinkala Musalula, and in our study, we used the NMF algorithm to calculate the sequencing data, which could be more sensitive to identify the main characteristic [16], and silhouette width analysis shows high credibility subtype identification (0.93 average silhouette width). Zhang et al. [17] have established a GSVA-related miRNA and mRNA signature. However, the subtype was not analyzed in their study, and the significant gene sets and pathways in their study were not screened by the subtype of PDAC, which could compromise the conclusion. After the subtype identification, the clinical data, including patient status, tumor classification, and carcinogenic habit, were calculated and our clustered cancer subtypes showed robust competency on distinguishing tumor classification. After common gene sets and pathways were identified among the 3 PDAC subtypes and LASSO regression, the glycolysis pathway and other two immune pathways were identified. Some previous research studies have focused on the glycolysis pathway in the carcinogenesis of PDAC. Dai Shang-nan et al. reported that glycolysis promotes the progression of pancreatic cancer and reduces cancer cell sensitivity to gemcitabine [18]. Zhang et al. established a glycolysis-related prognostic formula to predict the chemosensitivity of patients with PDAC [19]. The result from our study also illustrates the emergency role of the glycolysis pathway in PDAC using GSVA.

By analyzing the hub genes in the screened gene sets and pathways, the HIF-1 signaling pathway was identified as a distinct pathway, and the immune environment relevance shows that cancer-associated fibroblasts are significantly enriched in the upregulated hub genes. PDAC is a tumor with a high level of fibrosis, and a dense fibrotic matrix takes up 90% of tumorous bulk [20]. The origin of the fibrotic matrix has been widely studied, and cancer-associated fibroblasts (CAFs) have been illustrated to play an important role in tumorous fibrosis [21]. Chen et al. separated CAFs and normal fibroblasts (NFs) obtained from PDAC tissue, and CAFs showed strong glucose absorption and lactic acid production [22]. Compared with NFs, pyruvate kinase M2 (PKM2) in CAFs is upregulated. The finding hints that metabolic reprogramming occurs in CAFs with significant high expression of glucose. Some studies hint that the HIF-1 signaling pathway participates in tumorous fibrosis. Goodwin et al. demonstrated that some pivotal kinase in glucose could be activated by the HIF-1 pathway [23]. Our finding illustrates that glycolysis is a pivotal biologic process in PDAC with significant prognostic value, and the potential upstream mechanism is associated with the activation of the HIF-1 pathway. The downstream mechanism could be
abnormally activated glucose promote the trans-differentiation of CAFs.

Another light spot of our study is some found hub genes, namely, DCN, VCAN, B4GALT7, SDC1, SDC2, B3GALT6, B3GAT3, SDC3, GPC1, and XYLT2. Some cancer-related mechanism of these molecules has been reported: DCN encodes decorin, a class I SLRP that participates in collagen fibrillogenesis. In carcinogenesis, decorin could promote the development of cancer as a pan tyrosine kinase inhibitor [24]. Zhang et al. recently reported DCN is able to promote tumor invasion and migration in pancreatic cancer cells [25]. VCAN is a member of a large chondroitin sulfate proteoglycan family with hyaluronate-binding capacities. VCAN participates in cancer-related intercellular substance formation to promote tumor cell proliferation and invasion in multiple types of cancers [26,27]. VCAN was also reported to have an important role in the invasion phenotypes of PDAC.
Table 1: The relevance among subtypes and clinical data in TCGA-PDAC.

|                     | Subtype 1 (n = 78) | Subtype 2 (n = 17) | Subtype 3 (n = 81) | P value |
|---------------------|-------------------|-------------------|-------------------|---------|
| Gender              |                   |                   |                   | 0.848   |
| Male                | 40                | 11                | 45                |         |
| Female              | 38                | 6                 | 36                | 0.763   |
| Age (average age)   |                   |                   |                   |         |
| >65                 | 40 (73.5)         | 6                 | 37 (74.5)         | <0.01   |
| ≤65                 | 38 (60.0)         | 11                | 44 (56.5)         |         |
| Status (dead, %)    | 34 (43.6)         | 3 (17.6)          | 20 (24.7)         | <0.01   |
| Residual tumor (R0, %) | 41 (52.6)     | 13 (76.5)         | 52 (64.2)         | <0.01   |
| Tumor size (≤4 cm)  | 45 (57.7)         | 11 (64.7)         | 58 (61.7)         | 0.236   |
| TNM classification (%) |                |                   |                   |         |
| T1                  | 3 (3.8)           | 1 (5.9)           | 3 (3.7)           | <0.01   |
| T2                  | 9 (11.5)          | 6 (35.3)          | 9 (11.1)          |         |
| T3&4                | 66 (84.6)         | 8 (47.1)          | 69 (85.1)         |         |
| Tx (missing)        | 0                 | 2 (11.8)          | 0                 |         |
| M0                  | 35 (44.9)         | 5 (29.4)          | 40 (49.4)         | 0.893   |
| M1                  | 2 (2.6)           | 0                 | 2 (2.5)           |         |
| Mx (missing)        | 41 (52.6)         | 0                 | 39 (48.1)         |         |
| N0                  | 24 (30.8)         | 7 (41.2)          | 18 (22.2)         | 0.02    |
| N1                  | 54 (69.2)         | 7 (41.2)          | 61 (75.3)         |         |
| Nx (missing)        | 0                 | 3 (17.6)          | 2 (2.5)           |         |
| WHO classification  |                   |                   |                   |         |
| Stage I             | 10 (12.8)         | 6 (35.3)          | 5 (6.2)           | 0.02    |
| Stage II            | 64 (82.1)         | 9 (52.9)          | 72 (88.9)         |         |
| Stage III and IV    | 4 (5.1)           | 0                 | 4 (4.9)           |         |
| Stage x (missing)   | 0                 | 2 (11.8)          | 0                 |         |
| Pathological grade  |                   |                   |                   |         |
| G1                  | 7 (9.0)           | 11 (64.7)         | 12 (14.8)         | 0.02    |
| G2                  | 44 (56.4)         | 2 (11.8)          | 48 (59.3)         |         |
| G3 and G4           | 27 (34.6)         | 3 (17.6)          | 21 (25.9)         |         |
| Gx (missing)        | 0                 | 1 (5.9)           | 0                 |         |
| Alcohol history (YES, %) | 49 (62.8) | 6 (35.3)          | 40 (49.4)         | 0.04    |
| Smoking history (YES, %) | 24 (30.8) | 5 (29.4)          | 30 (37.0)         | 0.248   |

Table 2: The screened gene sets and pathways after univariable Cox regression analysis.

| Gene sets and pathways | HR     | HR.95L | HR.95H | P value |
|------------------------|--------|--------|--------|---------|
| T_GSE45365_WT_VS_IFNAR_KO_CD11B_DC_MCMV_INFECTION_DN | 5.03   | 4.94   | 5.23   | 0.003   |
| T_GSE20715_0H_VS_48H_OZONE_LUNG_DN | 2.92   | 3.04   | 1.17   | 0.005   |
| T_GSE13411_PLASMA_CELL_VS_MEMORY_BCELL_UP  | 3.73   | 1.92   | 7.74   | 0.014   |
| T_HALLMARK_GLYCOLYSIS | 8.97   | 8.43   | 9.25   | 0.001   |
| T_GSE19888_CTRL_VS_T_CELL_MEMBRANES_ACT_MAST_CELL_DN | 2.89   | 2.15   | 3.87   | 0.002   |

Figure 5: Continued.
B4GALT7, B3GALT6, and B3GAT3 encode three subtypes of galactosyltransferase. Galactosyltransferases are related to glycosaminoglycans and to proteoglycans in multiple tissues, including cancer development [28,29]. Syndecans are a family of transmembrane glycoproteins, and the syndecan-mediated calcium metabolism is associated with cell adhesion, the dysfunction of syndecans is a pivotal biologic process in tumor development [30]. In particular, SDC1 is also reported to facilitate tumor invasion via stimulating the EMT pathway in pancreatic
cancer cells [31]. SDC2 can promote epithelial-mesenchymal transition in colon cancer [32]. SDC3 could also promote melanoma tumors through the regulation of the HIF pathway [33]. Interestingly, the significant differential expression has been screened and these genes are identified as the hub genes in the glycolysis pathway after GSVA in PDAC, which needs further research on their behaviors in carcinogenesis. The full name of XYL2 is xylosyltransferase 2, and XYL2 participated in the proteoglycan (PG) biochemistry of multiple tumor tissues.
Upregulation of GPC1 is associated with an unfavorable prognosis of PDAC [35]. Comprehensively, the findings are mostly focusing their potential roles in cancer signaling transduction. Based on this study, the mechanism of these upregulated hub genes on restraining tumor immunity and promoting transdifferentiation of CAFs and other verification based on clinical samples needs to be studied further.

5. Conclusions

In this study, we established a new clustering method of PDAC subtype by machine-learning method and verified its functional competency in two cohorts from the database. Then, we build a GSVA-based prognostic formula by subtype clustering, Cox, and LASSO regression and validated its predicting competency on the relevance of TCGA-PDAC clinical characteristics and survival data in two combined GEO datasets after batch normalization. Additionally, 10 upregulated hub genes were identified and validated in three significant GSVA-based gene sets, and the function of the gene sets and hub genes in PDAC tumor immunity was predicted as promoting the transdifferentiation of CAFs.

Data Availability

The PAAD dataset was downloaded from the TCGA database (https://tcga-data.nci.nih.gov/tcga/), and GSE28735 and GSE62452 were downloaded from the GEO database (http://www.ncbi.nlm.nih.gov/geo/).

Disclosure

Deyu Zhang and Meiqi Wang are co-first authors.

Conflicts of Interest

The authors declare that they have no conflicts of interest.
Authors’ Contributions
Zhendong Jin and Haojie Huang designed the study. Deyu Zhang and Meiqi Wang collected data, exerted statistical analysis, and wrote the manuscript. Lisi Peng, Xiaoli Yang, Fang Cui, Hua Yin, Chuanchao Xia, and Keliang Li visualized the result. All authors discussed the results and approved the final manuscript. Deyu Zhang and Meiqi Wang equally contributed to this work.

Acknowledgments
This work was supported by the National Natural Science Foundation of China (grant no. 82170657). The author, Deyu Zhang, would like to show great appreciation to his fiancee Meiqi Wang for her love and support in academic research and daily life of all of their days.

Supplementary Materials
Supplementary Figure 1: (A) identification of best cutoff of cluster. (B) The distribution of each cluster by the PCA method in the factoextra package. (C) Survival analysis of GSE28735 and GSE62452 by clusters. (D) Identification of the value of grouping by silhouette width plots. (E) Visualization of each cluster using the NMF method. (Supplementary Materials)

References
[1] R. L. Siegel, K. D. Miller, H. E. Fuchs, and A. Jemal, “Cancer statistics, 2021,” CA: A Cancer Journal for Clinicians, vol. 71, no. 1, pp. 7–33, 2021.
[2] L. C. Chu, M. G. Goggins, and E. K. Fishman, “Diagnosis and detection of pancreatic cancer,” The Cancer Journal, vol. 23, no. 6, pp. 333–342, 2017.
[3] T. Kamisawa, L. D. Wood, T. Itoi, and K. Takaori, “Pancreatic cancer,” The Lancet, vol. 388, no. 10039, pp. 73–85, 2016.
[4] U. M. Mahajan, E. Langhoff, E. Goni et al., “Immune cell and stromal signature associated with progression-free survival of patients with resected pancreatic ductal adenocarcinoma,” Gastroenterology, vol. 155, no. 5, pp. 1625–1639, 2018.
[5] S. Yu, Y. Li, Z. Liao et al., “Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for the detection of pancreatic ductal adenocarcinoma,” Gut, vol. 69, no. 3, pp. 540–550, 2020.
[6] M. Strijker, E. C. Soer, M. Pastena et al., “Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma,” International Journal of Cancer, vol. 146, no. 5, pp. 1445–1456, 2020.
[7] B. Li, Y. Cui, M. Diehn, and R. Li, “Development and validation of an individualized immune prognostic signature in early-stage nonsquamous non-small cell lung cancer,” JAMA Oncology, vol. 3, no. 11, pp. 1529–1537, 2017.
[8] D. Zhang, S. Zhou, and B. Liu, “Identification and validation of an individualized EMT-related prognostic risk score formula in gastric adenocarcinoma patients,” BioMed Research International, vol. 2020, Article ID 7082408, 15 pages, 2020.
[9] X.-P. Tian, W.-J. Huang, H.-Q. Huang et al., “Prognostic and predictive value of a microRNA signature in adults with T-cell lymphoblastic lymphoma,” Leukemia, vol. 33, no. 10, pp. 2454–2465, 2019.
[10] L. Qu, Z.-L. Wang, Q. Chen et al., “Prognostic value of a long non-coding RNA signature in localized clear cell renal cell carcinoma,” European Urology, vol. 74, no. 6, pp. 756–763, 2018.
[11] S. Hänzelmann, R. Castelo, and J. Guinney, “GSVA: gene set variation analysis for microarray and RNA-seq data,” BMC Bioinformatics, vol. 14, p. 7, 2013.
[12] L. Franco-Luzón, S. García-Mulero, R. Sanz-Pamplona, G. Melen, D. Ruano, and A. Lassaletta, “Genetic and immune changes associated with disease progression under the pressure of oncolytic therapy in A neuroblastoma outlier patient,” Cancers, vol. 12, no. 5, 2020.
[13] J. T. Leek, W. E. Johnson, H. S. Parker, A. E. Jaffe, and J. D. Storey, “The sva package for removing batch effects and other unwanted variation in high-throughput experiments,” Bioinformatics, vol. 28, no. 6, pp. 882–883, 2012.
[14] T. Xu, T. D. Le, L. Liu et al., “CancerSubtypes: an R/Bioconductor package for molecular cancer subtype identification, validation and visualization,” Bioinformatics, vol. 33, no. 19, pp. 3131–3133, 2017.
[15] L. Peng, L. Zhuang, K. Lin et al., “Downregulation of GSTM2 enhances gemcitabine chemosensitivity of pancreatic cancer in vitro and in vivo,” Pancreatology, vol. 21, no. 1, pp. 115–123, 2021.
[16] P. Wu, M. An, H.-R. Zou, C.-Y. Zhong, W. Wang, and C.-P. Wu, “A robust semi-supervised NMF model for single cell RNA-seq data,” PeerJ, vol. 8, Article ID e10091, 2020.
[17] J. Zhang, J. Gu, S. Guo et al., “Establishing and validating a pathway prognostic signature in pancreatic cancer based on miRNA and mRNA sets using GSVA,” Aging, vol. 12, no. 22, pp. 22840–22858, 2020.
[18] S. Dai, Y. Peng, Y. Zhu et al., “Glycodies promotes the progression of pancreatic cancer and reduces cancer cell sensitivity to gemcitabine,” Biomedicine & Pharmacotherapy, vol. 121, Article ID 109521, 2020.
[19] X. P. Zhang, Q. Chen, Q. Liu et al., “Development and validation of glycolysis-related prognostic score for prediction of prognosis and chemosensitivity of pancreatic ductal adenocarcinoma,” Journal of Cellular and Molecular Medicine, vol. 25, no. 12, pp. 5615–5627, 2021.
[20] Y. Luo, Y. Yang, M. Liu et al., “Oncogenic KRAS reduces expression of FGF21 in acinar cells to promote pancreatic tumorigenesis in mice on a high-fat diet,” Gastroenterology, vol. 157, no. 5, pp. 1413.e11–1428.e11, 2019.
[21] M. V. Apte, J. S. Wilson, A. Lugea, and S. J. Pandol, “A starring role for stellate cells in the pancreatic cancer microenvironment,” Gastroenterology, vol. 144, no. 6, pp. 1210–1219, 2013.
[22] S. Chen, X. Chen, T. Shan et al., “MiR-21-mediated metabolic alteration of cancer-associated fibroblasts and its effect on pancreatic cancer cell behavior,” International Journal of Biological Sciences, vol. 14, no. 1, pp. 100–110, 2018.
[23] J. Goodwin, H. Choi, M.-H. Hisieh et al., “Targeting hypoxia-inducible factor-1α/pyruvate dehydrogenase kinase 1 axis by dichloroacetate suppresses bleomycin-induced pulmonary fibrosis,” American Journal of Respiratory Cell and Molecular Biology, vol. 58, no. 2, pp. 216–231, 2018.
[24] S. Kising, G. Natarajan, R. Pothuraju, A. Shah, S. Batra, and S. Kaur, “Implications of prognosis-associated genes in pancreatic tumor metastasis: lessons from global studies in bioinformatics,” Cancer Metastasis Reviews, vol. 40, 2021.
13

[25] L. Zhang, C. Liu, H. Gao et al., “Study on the expression profile and role of decorin in the progression of pancreatic cancer,” Aging, vol. 13, no. 11, pp. 14989–14998, 2021.

[26] M. Ween, M. Oehler, and C. Ricciardelli, “Role of versican, hyaluronan and CD44 in ovarian cancer metastasis,” International Journal of Molecular Sciences, vol. 12, no. 2, pp. 1009–1029, 2011.

[27] A. Papadas and F. Asimakopoulos, “Versican in the tumor microenvironment,” Advances in Experimental Medicine & Biology, vol. 1272, pp. 55–72, 2020.

[28] C. Sandler-Wilson, J. A. Wambach, B. A. Marshall et al., “Phenotype and response to growth hormone therapy in siblings with B4GALT7 deficiency,” Bone, vol. 124, pp. 14–21, 2019.

[29] F. Jacob, S. Alam, M. Konantz et al., “Transition of mesenchymal and epithelial cancer cells depends on α1-4 galactosyltransferase-mediated glycosphingolipids,” Cancer Research, vol. 78, no. 11, pp. 2952–2965, 2018.

[30] N. Betriu, J. Bertran-Mas, A. Andreeva, and C. E. Semino, “Syndecans and pancreatic ductal adenocarcinoma,” Biomolecules, vol. 11, no. 3, 2021.

[31] X. Chen, H. Zhao, C. Chen et al., “The HPA/SDC1 axis promotes invasion and metastasis of pancreatic cancer cells by activating EMT via FGF2 upregulation,” Oncology Letters, vol. 19, no. 1, pp. 211–220, 2020.

[32] R. Hua, J. Yu, X. Yan et al., “Syndecan-2 in colorectal cancer plays oncogenic role via epithelial-mesenchymal transition and MAPK pathway,” Biomedicine & Pharmacotherapy, vol. 121, Article ID 109630, 2020.

[33] P.-F. Endika, E.-M. Leire, B. Alexandre et al., “Hypoxia promotes syndecan-3 expression in the tumor microenvironment,” Frontiers in Immunology, vol. 11, Article ID 586977, 2020.

[34] B. Ferencz, E. Condac, N. Poudel et al., “Xylosyltransferase 2 deficiency and organ homeostasis,” Glycoconjugate Journal, vol. 37, no. 6, pp. 735–765, 2020.

[35] H. Lu, F. Niu, F. Liu, J. Gao, Y. Sun, and X. Zhao, “Elevated glypican-1 expression is associated with an unfavorable prognosis in pancreatic ductal adenocarcinoma,” Cancer Medicine, vol. 6, no. 6, pp. 1181–1191, 2017.